University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > HIV Meds Quarterly > Winter 2010 > Lopinavir/ritonavir
Lopinavir/ritonavir and Buprenorphine
gray line
transparent gif
transparent gif

This pharmacokinetic study investigated the interaction between lopinavir/ritonavir (800/200 mg given once daily) and buprenorphine/naloxone in 12 HIV-seronegative subjects who were on stable buprenorphine therapy.

After administration of lopinavir/ritonavir for at least 10 days, the buprenorphine AUC and Cmax were not significantly different from baseline values. For norbuprenorphine, the primary metabolite of buprenorphine, the Cmax was lower during coadministration with lopinavir/ritonavir (73.7 vs 52.7 ng•hr/mL, p < .05) whereas the AUC was not significantly lower (5.29 vs 3.11 ng/mL). Concentrations of naloxone were unchanged, and the lopinavir AUC and Cmin were not significantly different from those of two historical comparators.

Clinical Bottom Line

Based on these data, no dosage modification of either buprenorphine/naloxone or lopinavir/ritonavir is needed when these drugs are coadministered.

References

  1. Bruce D, Altice F, Moody D, et al. Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Once-Daily Lopinavir/Ritonavir. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco. Abstract 620.
transparent gif